Clinical Trials
26 trialsNCT06285357 2025-11-20
The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection.
Lo.Li.Pharma s.r.l
Phase NA Recruiting
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02578680 2024-09-20
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03950674 2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05625308 2022-12-22
Effect of Natural Compounds on the Severity of HPV-induced Cervical Lesions
Lo.Li.Pharma s.r.l
Phase NA Completed
NCT04265534 2022-09-21
KEAPSAKE
Calithera Biosciences, Inc
Phase 2 Terminated
NCT00998946 2021-11-05
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00606502 2021-03-05
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT01118624 2020-01-07
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Acrotech Biopharma Inc.
Phase 2 Completed
NCT00554827 2020-01-03
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
NCT00722553 2019-12-17
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
Phase 2 Completed
NCT02106650 2019-11-20
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Acrotech Biopharma Inc.
Phase 2 Completed
NCT03349333 2019-10-01
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT01165021 2019-09-25
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01999738 2019-02-07
Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors
Endocyte
Phase 1 Completed
NCT03011320 2019-02-07
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
Endocyte
Phase 1 Completed
NCT03422289 2018-02-06
Improved Effects of MI Plus Alpha-LA in PCOS
Lo.Li.Pharma s.r.l
Phase NA Completed
NCT02013362 2017-11-09
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Mundipharma K.K.
Phase 1/2 Completed
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT01953536 2014-12-19
Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Endocyte
Phase 2 Withdrawn
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated
NCT01057589 2013-09-18
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00609518 2010-12-28
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00034463 2006-07-19
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed